(Total Views: 518)
Posted On: 02/12/2025 12:34:03 AM
Post# of 155807
$400m is 50% less than for some recent Phase 1 drugs, build-out included & royalties.
LL:
Non-toxic. Or disease to disease.
Great Inclusion/Exclusion criteria.
1600 patient data across about 6 different diseases with no safety signal. None post trial FDA reports.
Not an industry normal @ Phase 2.
Down the road, for many reasons, might include straight to Phase 3.
LL:
Non-toxic. Or disease to disease.
Great Inclusion/Exclusion criteria.
1600 patient data across about 6 different diseases with no safety signal. None post trial FDA reports.
Not an industry normal @ Phase 2.
Down the road, for many reasons, might include straight to Phase 3.
(2)
(0)
